ClinicalTrials.gg

Program

RSV+HMPV vaccine

Also written as “Investigational RSV+hMPV vaccine”.

Its studies are mostly in Respiratory Syncytial Virus Infections, led by Sanofi.

Furthest: phase 2, since Nov 11, 20242 company-led studies, 2 open or runningNext primary completion: Jan 18, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi22 open or runningphase 2since Nov 11, 2024Nov 11, 2024Jan 18, 2027phase 2 · NCT06686654

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 11, 2024First study: phase 2 study in Respiratory Syncytial Virus InfectionsFirst studyNCT06686654 · 1,530 enrolled · United States
  2. Jul 21, 2026Phase 2 study in Respiratory Syncytial Virus ImmunizationNCT07734649 · 2,400 planned · United States

Ahead

  1. Jan 18, 2027Primary completion: phase 2 study in Respiratory Syncytial Virus InfectionsNCT06686654
  2. May 3, 2028Primary completion: phase 2 study in Respiratory Syncytial Virus ImmunizationNCT07734649

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“RSV+HMPV vaccine”name, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07734649Respiratory Syncytial Virus Immunization · United States2RecruitingMay 3, 20282,400
NCT06686654Respiratory Syncytial Virus Infections · United States2Active, not recruitingJan 18, 20271,530

How it is read

Names in the registry

  • “RSV+HMPV vaccine”, 1 entry
  • “Investigational RSV+hMPV vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.